Exact Sciences (EXAS)

• Market cap: $9.15B
• 1 day: -0.50%
• 5 days: -2.71%
• 1 month: -9.21%
• 3 months: -7.18%
• 6 months: -17.46%
• Year to date: -13.47%
• 1 year: -22.17%
• 5 years: -50.73%
• 10 years: 103.39%
• Sector: Healthcare
• Industry: Medical Laboratories

About: Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a noninvasive stool-based DNA test, is a precancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening.

Employees: 7,000

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

123% more call options, than puts

Call options by funds: $251M | Put options by funds: $112M

0% more first-time investments, than exits

New positions opened: 86 | Existing positions closed: 86

9% less repeat investments, than reductions

Existing positions increased: 176 | Existing positions reduced: 193

3.06% less ownership

Funds ownership: 101.46% [Q3] → 98.4% (-3.06%) [Q4]

4% less funds holding

Funds holding: 586 [Q3] → 562 (-24) [Q4]

20% less capital invested

Capital invested by funds: $12.8B [Q3] → $10.2B (-$2.54B) [Q4]

22% less funds holding in top 10

Funds holding in top 10: 9 [Q3] → 7 (-2) [Q4]

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $65 32% upside
• Avg. target: $71 45% upside
• High target: $86 75% upside

5 analyst ratings

• positive: 5 100%
• neutral: 0 0%
• negative: 0 0%

B of A Securities Derik De Bruin 45% 1-year accuracy 9 / 20 met price target	32% upside $65	Buy Maintained	20 Feb 2025
Barclays Luke Sergott 31% 1-year accuracy 16 / 52 met price target	32% upside $65	Overweight Maintained	20 Feb 2025
Benchmark Bruce Jackson 40% 1-year accuracy 21 / 52 met price target	32% upside $65	Buy Reiterated	13 Jan 2025
TD Cowen Dan Brennan 41% 1-year accuracy 12 / 29 met price target	75% upside $86	Buy Maintained	26 Nov 2024
BTIG Mark Massaro 52% 1-year accuracy 15 / 29 met price target	52% upside $75	Buy Maintained	26 Nov 2024